SuperworthShattuck Labs STTK
- Market cap
- $551M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- a sliver of sales
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $1M
- −67% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- n/m
- not a meaningful number
Shattuck Labs' trailing earnings are negative, so it has no PE. Revenue was $1M over the last twelve months, down 67% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $686K+224% | $714K+83% | $1.1M+1856% | $1.6M+705% | $3M+337% | $0 | $0 | $0 | $1M−67% | $0 | $0 | $0 | |
| R&D | $24.2M+28% | $15.2M−30% | $16.3M−2% | $19.2M+6% | $16.3M−33% | $15.4M+1% | $9.9M−39% | $8.7M−55% | $7.6M−53% | $9.1M−41% | $10.9M+10% | $11.7M+35% |
| SG&A | $5.1M−23% | $4.4M−7% | $4.9M−3% | $5.3M+12% | $4.6M−9% | $4.2M−4% | $4.5M−9% | $4.4M−18% | $4.1M−11% | $4.3M+2% | $4.6M+3% | $4.5M+2% |
| −$28.6M+13% | −$19M−28% | −$20M−8% | −$23M+1% | −$17.9M−37% | −$19.6M+4% | −$14.4M−28% | −$13M−43% | −$10.7M−40% | −$13.4M−32% | −$15.5M+8% | −$16.2M+24% | |
| Net income | −$27.5M+12% | −$17.7M−30% | −$18.5M−11% | −$21.6M+1% | −$16.7M−40% | −$18.7M+6% | −$13.7M−26% | −$12.5M−42% | −$10.1M−40% | −$12.6M−33% | −$14.8M+8% | −$15.2M+22% |
| −$0.65+12% | −$0.41−32% | −$0.37−25% | −$0.42−16% | −$0.33−49% | −$0.37−10% | −$0.27−27% | −$0.24−43% | −$0.14−58% | −$0.12−68% | −$0.13−52% | −$0.12−50% | |
| 42.5M+0% | 43M+2% | 50.6M+19% | 50.8M+20% | 50.8M+20% | 50.8M+18% | 51M+1% | 51M+0% | 72.2M+42% | 103.7M+104% | 112.2M+120% | 129.8M+155% |
EPS, diluted: 7 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Shattuck Labs' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| STTKShattuck Labs | $551M | n/m | n/a | n/m | −67% | n/m | |
| PBYIPuma Biotechnology | $568.9M | 21.2× | 12.3× | 2.5× | −3% | 11.6% | |
| IRWDIronwood Pharmaceuticals | $571.7M | 4.5× | 14.9× | 1.5× | +26% | 33.4% | |
| ZVRAZevra Therapeutics | $582.6M | 10.5× | 12.3× | 4.3× | +119% | 42.8% | |
| CRMDCorMedix | $611.9M | 3.7× | 4.0× | 1.3× | +281% | 40.5% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| COLLCollegium Pharmaceutical | $747.5M | 18.5× | 19.1× | 0.9× | +14% | 5.9% | |
| ABUSArbutus Biopharma | $831M | 5.4× | 5.6× | 4.6× | n/m | 84.2% | |
| AMPHAmphastar Pharmaceuticals | $1.1B | 14.8× | 20.6× | 1.5× | +1% | 10.8% | |
| OMEROmeros | $1.2B | 10.9× | 11.7× | n/m | n/m | n/m | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $597.2M | 11.5× | 13.6× | 1.5× | +11% | 11.6% |
More on Shattuck Labs
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .